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This study investigated the inhibitory eﬀect of probiotic Enterococcus faecium WB2000 on bioﬁlm formation by cariogenic
streptococci. The ability of E. faecium WB2000 and JCM5804 and Enterococcus faecalis JCM5803 to inhibit bioﬁlm formation
by seven laboratory oral streptococcal strains and 13 clinical mutans streptococcal strains was assayed. The Enterococcal strains
inhibited bioﬁlm formation in dual cultures with the mutans streptococcal strains Streptococcus mutans Xc and Streptococcus
sobrinusJCM5176(P<0.05),butnotwiththenoncariogenicstreptococcalstrains.EnterococcusfaeciumWB2000inhibitedbioﬁlm
formation by 90.0% (9/10) of the clinical S. mutans strains and 100% (3/3) of the clinical S. sobrinus strains. After culturing, the
pH did not diﬀer between single and dual cultures. The viable counts of ﬂoating mutans streptococci were lower in dual cultures
withE. faecium WB2000 than in single cultures. Enterococcus faecium WB2000 acted as a probiotic bacterial inhibitor of cariogenic
streptococcal bioﬁlm formation.
1.Introduction
Dental caries is a very common chronic disease arising
from the interplay among the oral ﬂora, teeth, and dietary
factors.Themajoretiologicalplayersarethetwoα-hemolytic
“mutans group” streptococci: Streptococcus mutans and
Streptococcus sobrinus [1, 2] .T h e s eb a c t e r i aa d h e r et e n a -
ciously to glucan-coated surfaces, produce large amounts of
extracellular polysaccharides, and are highly acidogenic and
acid tolerant [3, 4] .T h ec o l o n i z a t i o no fd e n t a lp l a q u eb y
S. mutans and S. sobrinus p l a y sac a u s a t i v er o l ei nd e n t a l
caries. Sugar metabolism is central to the behavior of mutans
streptococci, and sucrose, the most cariogenic dietary carbo-
hydrate, is used to produce the extracellular polysaccharides
that form the bioﬁlm matrix, which aids in the association
of mutans streptococci with dental plaque. Once the mutans
streptococci bioﬁlm becomes part of the dental plaque,
the acidic byproducts of sugar fermentation dissolve tooth
enamel, eventually resulting in dental caries [4]. Dental
plaque contains numerous genetically distinct types of bac-
teria that live in close juxtaposition on host surfaces [5]. The
“viridans group” streptococci, such as Streptococcus sangui-
nis, Streptococcus oralis, Streptococcus mitis,a n dStreptococcus
gordonii, are noncariogenic streptococci. Together with Acti-
nomyces spp., they play an important role as initial colonizers
of the tooth surface in the formation of dental plaque [6].
Probiotic bacteria, deﬁned as live microorganisms that
confer a health beneﬁt on the host when administered in
adequate amounts (FAO/WHO 2001), are thought to play a
role in the maintenance of oral health [7]. Studies examining
the eﬀects of oral probiotics demonstrated that the con-
sumption of products containing Lactobacillus rhamnosus or
Lactobacillus reuteri reduces the number of mutans strepto-
cocci in the oral cavity [8, 9]. The use of probiotic tablets
containing Biﬁdobacterium spp. normalized the microbiota
in patients with periodontitis and gingivitis, as compared
withacontrolgroup[10].Lactobacillussalivariustakenorally
improved the periodontal health of healthy volunteers, par-
ticularly smokers, and reduced the numbers of periodontal
bacteria in subgingival plaque to patients with oral malodor
reduced the malodor and bleeding on probing from the
periodontal pocket [13]. Therefore, the probiotic bacteria2 International Journal of Dentistry
used in the human oral cavity are mainly Lactobacillus spp.
and Biﬁdobacterium spp., whereas Enterococcus strains have
been used in human systemic health, especially as probiotic
supplements to counter gastrointestinal diseases [14, 15],
and they are widely used as veterinary feed supplements
[16, 17].
Enterococci are facultative anaerobic, Gram-positive
cocci that form a part of the normal gastrointestinal tract
ﬂora in animals and humans. They are also frequently found
in fermented food that is consumed raw, such as cheese and
m e a t ,a sw e l la si nv e g e t a b l e sa n do l i v e s[ 18]. The genus
Enterococcus includes at least 23 species, two of which, E.
faecalis and E. faecium, account for more than 95% of the
clinically important isolates. Traditionally, they are regarded
as low-grade pathogens, but they have emerged as an
increasingly important cause of nosocomial infections [19].
They are rarely found in the healthy human oral cavity, yet E.
faecalis appears to occur frequently, albeit in low numbers, in
primaryrootcanalinfections,especiallyinteethwithcoronal
leakage [20]. The clinical use of E. faecalis and E. faecium
during food fermentation and as probiotics demands careful
safety evaluation [21]. Recently, Kumada et al. reported that
E. faecium 129BIO 3B (Biofermin Pharmaceutical, Kobe,
Japan) inhibited bioﬁlm formation in dual cultures with S.
mutans,S.sobrinus,andS.sanguinisinvitro[22].Toexamine
the suitability of using probiotic E. faecium WB2000, which
was isolated from the feces of a healthy human and is
contained in the Japanese gastrointestinal agent Strong
Wakamoto (Wakamoto Pharmaceutical, Tokyo, Japan), to
maintain oral health, this study examined the inhibition
of bioﬁlm formation by viridans group streptococci or
cariogenic mutans streptococci in dual cultures with E.
faecium WB2000 using 96-well microtiter plate assays.
2.Methods and Materials
2.1. Bacterial Strains and Culture Conditions. Enterococcus
faeciumWB2000previouslyclassiﬁedasStreptococcusfaecalis
[23], which was provided by Wakamoto Pharmaceutical, as
well as E. faecium JCM5804, E. faecalis JCM5803, S. mutans
JCM5705 and Xc, S. sobrinus JCM5176, S. gordonii DL1
(Challis), S. sanguinis American Type Culture Collection
(ATCC) 10556, S. oralis ATCC 10557, S. mitis ATCC 903,
10 clinical strains of S. mutans (SMW01, SMW03, SMW08,
SMW09, SMW10, SMW11, SMW13, SMW15, SMW22, and
SMF01), and three clinical strains of S. sobrinus (SSW07,
SSW14, and SSW24) were examined. The 13 clinical isolates
of mutans streptococci, which have the ability to form,
bioﬁlms, were isolated from the saliva of 35 healthy adult
volunteers (23 males and 12 females, aged 25–61 years, with
ameanageof38.5±9.8y ears[ ±SD])usingselectivemedium
(CRT bacteria; Ivoclar Vivadent AG, Schaan, Principality of
Liechtenstein) and the polymerase chain reaction. The vol-
unteers consisted of workers employed by Wakamoto Phar-
maceutical Co. (Tokyo, Japan) and coauthors at the Fukuoka
Dental College. Permission for this study was obtained from
the Ethics Committee for Clinical Research at Wakamoto
Pharmaceutical Co. and at the Fukuoka Dental College
(approval number, 2010-02 and 163, resp.). After growth to
stationary phase, the bacteria were suspended into skim milk
and stored as 1-mL aliquots in sterile tubes at −80◦C.
The ability of the clinical mutans streptococcal isolates
to form a bioﬁlm in a 24-well (ﬂat-bottom) microtiter plate
(Sumitomo Bakelite Co., Tokyo, Japan) was determined as
follows. A single colony was cultured in 1mL of GAM both
with 2.0% sucrose for 24h, and the supernatant was dis-
carded. The well was rinsed three times with sterile distilled
water (d-water), air-dried, and stained with 0.1% crystal
violet solution for 15min. After staining, the well was rinsed
with d-water to remove excess dye and air-dried. The pres-
ence of a bioﬁlm mass was conﬁrmed by visual assessment.
2.2. Human Saliva Preparation. Whole saliva samples were
collected from three healthy human participants (mean age,
31.7 ± 5.5 years) by their chewing paraﬃn gum. The mixed
saliva was centrifuged and 10000×gf o r2 0 m i na t4 ◦C,
and the supernatant was incubated at 56◦Cf o r3 0 m i nt o
inactivate degradative enzymes. The samples were sterilized
using a sterile membrane ﬁlter (pore size, 0.22μm; Millipore,
Billerica, MA, USA) and used immediately for the bioﬁlm
formation assay.
2.3. Bioﬁlm Formation Assay in 96-Well Microtiter Plates.
Bioﬁlm formation by each strain was assayed using a
described method [22]. To start the bioﬁlm formation assay,
precultures of each bacterium stored at −80◦Cw e r eg r o w n
in 10mL of brain heart infusion (BHI) medium (Difco Lab-
oratories, Detroit, MI, USA) for 24h at 37◦C to full growth.
To evaluate bioﬁlm formation in cocultures of Enterococcus
spp. and oral Streptococcus spp., 20μL of an enterococcal cell
suspension and 20μL of the other bacterial cell suspension
were mixed in a well of a 96-well (ﬂat-bottom) microtiter
plate (Nunc A/S, Roskilde, Denmark), along with 160μL
of tryptic soy broth (without dextrose, supplemented with
0.25% sucrose; TSBS; Wako Pure Chemical Industries,
Osaka, Japan), after coating the plates with whole saliva for
30min at 37◦C. To evaluate bioﬁlm formation by single
cultures, 20μL of bacterial cell suspension and 180μLo f
T S B Sw e r ea d d e dt oe a c hw e l l .T h ep l a t e sw e r ei n c u b a t e d
at 37◦C for 16h under anaerobic conditions, and the liquid
medium was removed. The wells were rinsed a second time
with d-water, air-dried, and stained with 0.25% safranin
for 15min. After staining, the plates were rinsed with d-
water to remove excess dye and then air-dried. The bioﬁlm
mass was dissolved with ethanol, and the stained bioﬁlm was
quantiﬁed by measuring the absorbance at 492nm using a
microplate reader (Sunrise Rainbow Thermo; Tecan Group,
M¨ annedorf, Switzerland). The pH of the supernatant was
determined before and after culturing for 16h.
2.4. Determination of the Viable Bacterial Count. To eval-
uate the change in bacterial cell numbers in the bioﬁlm
formation assay, diluted supernatant of the reaction mixture
was cultured on GAM (Nissui, Tokyo, Japan) agar plates
containing 2.0% sucrose for enterococci or on GAM agar
platescontaining2.0%sucroseand0.2unitsmL−1 bacitracin
(Sigma, St. Louis, MO, USA) for mutans group streptococci.International Journal of Dentistry 3
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Figure 1: Inhibitory eﬀects of E. faecium WB2000 and JCM5804
andE.faecalisJCM5803onbioﬁlmformationbylaboratorymutans
group streptococci. WB2000, E. faecium WB2000; JCM5804, E. fae-
ciumJCM5804;JCM5803,E.faecalisJCM5803;JCM5705,S.mutans
JCM5705; Xc, S. mutans Xc; JCM5176, S. sobrinus JCM5176. Black
bars: single culture; dark gray bars: dual culture with E. faecium
WB2000; light gray bars: dual culture with E. faecium JCM5804;
white bars: dual culture with E. faecalis JCM5803. ∗P<0.05 versus
single culture.
After a 24 to 48h incubation at 37◦Cu n d e ra n a e r o b i c
conditions, the viable bacteria were counted.
2.5. Reproducibility and Statistical Analysis. Each assay was
performed in at least three wells per plate, and at least three
independent replicates were performed. The diﬀerences in
bioﬁlm formation by the laboratory streptococcal strains
between single cultures and dual cultures with the entero-
coccal strains were analyzed using the Kruskal-Wallis test.
For paired comparisons of bioﬁlm formation using clinical
mutans streptococci and E. faecium WB2000, the Mann-
Whitney test was used. Diﬀerences at the 0.05 level were
considered statistically signiﬁcant.
3. Results
3.1. Eﬀect of E. faecium and E. faecalis on Streptococcal
Bioﬁlms. The bioﬁlm formation analyses of single cultures
showed that E. faecium WB2000 and JCM5804 and E. faecalis
JCM5803 produced little bioﬁlm (Figure 1, lines 1–3). The
viridans group streptococci also made little or no bioﬁlm,
except for S. oralis ATCC 10557 (data not shown). The
Enterococcus strains did not inhibit bioﬁlm formation by S.
oralis, and a mixture of the other viridans group strains
and Enterococcus strains did not make a bioﬁlm. S. mutans
JCM5705 and Xc and S. sobrinus JCM5176 made bioﬁlms in
single cultures (Figure 1, lanes 4–6), and every Enterococcus
strain inhibited this bioﬁlm formation. In particular, the
bioﬁlm formation by S. mutans Xc and S. sobrinus JCM5176
was signiﬁcantly inhibited (P<0.05).
Subsequently, 10 clinical S. mutans strains and three
clinicalS.sobrinusstrainswereexamined.Thesinglecultures
resulted in various amounts of bioﬁlm formation (Figure 2,
lanes 1–13). The bioﬁlm formation was reduced signiﬁcantly
in dual cultures of nine S. mutans (90.0%) and three S.
sobrinus (100%) clinical strains with E. faecium WB2000. E.
faecium WB2000 and JCM5804 and E. faecalis JCM 5803 had
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Figure 2: Inhibitory eﬀects of E. faecium WB2000 on bioﬁlm
formation by clinical mutans group streptococci. SMWs and SMF,
clinical S. mutans strains; SSWs, clinical S. sobrinus strains. Black
bars: single culture; white bars: dual culture with E. faecium
WB2000. ∗P<0.05 versus single culture.
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Figure 3: Viable bacterial counts of strains of mutans group
streptococciinsingleculturesat0and16handindualcultureswith
E. faecium WB2000 at 16h (log10CFU mL−1). JCM5705, S. mutans
JCM5705;Xc,S.mutansXc;JCM5176,S.sobrinusJCM5176;SMWs
and SMF, clinical S. mutans strains; SSWs, clinical S. sobrinus
strains.
similar eﬀects on reducing bioﬁlm formation. The pH in the
single cultures of S. mutans and S. sobrinus ranged from 4.6
to 4.8, and the pH in the single culture of E. faecium WB2000
was 4.9. The pH of the dual cultures of mutans streptococci
with E. faecium WB2000 was 4.8–4.9.
3.2. Viable Bacterial Count. Av i a b l ec o u n tw a sp e r f o r m e d
to reveal whether the decrease in streptococcal bioﬁlm
formation was caused by the death of bacterial cells or by
another factor such as inhibition of cell adhesion. Figures
3 and 4 show the viable bacterial counts of mutans group
streptococci and E. faecium WB2000 in single cultures at 0
and 16h and in dual cultures at 16h. After culturing, the
numbers of all of the bacterial strains in the dual cultures
were lower than those in single cultures. The numbers of
nine of the mutans streptococci in dual cultures with E.
faecium WB2000 at 16h were reduced in comparison with
those at 0h. The pattern of the increase or decrease in the
numbers of streptococci and enterococci varied. In dual
cultures of S. mutans SMW09 and E. faecium WB2000, in
which bioﬁlm formation was not inhibited, the number
of E. faecium WB2000 was markedly reduced (Figure 4,
lane 9).4 International Journal of Dentistry
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Figure 4: Viable bacterial counts of E. faecium WB2000 in single
cultures at 0 and 16h and in dual cultures with strains of mutans
group streptococci at 16h (log10CFU mL−1).
4. Discussion
This study evaluated the capacity of E. faecium WB2000 to
inhibit bioﬁlm formation by oral viridans group and mutans
group streptococci. This organism markedly inhibited
bioﬁlm formation by mutans streptococci, as reported previ-
ously [22], but did not inhibit bioﬁlm formation by S. oralis
in the viridans group. The other three viridans group strep-
tococci formed little or no bioﬁlm in single cultures, and the
combinations of viridans group streptococci with Enterococ-
cus spp. resulted in equal or reduced total bioﬁlm mass com-
paredwiththesingleenterococcalcultures.Standaretal.[24]
reportedthatS.mitisfailedtoformbioﬁlmstructuresinsim-
ilarinvitroassays,butthatthecombinationofS.mitiswithS.
mutans resulted in an increased total bioﬁlm mass compared
with cultures of S. mutans alone. Bacterial interactions are
veryimportantforbioﬁlmformation.Toconﬁrmthespeciﬁc
inhibition of cariogenic streptococci by E. faecium WB2000,
a future study should examine multiple bacteria.
In general, E. faecium WB2000 inhibited bioﬁlm forma-
tion by the clinical mutans group streptococci, except for S.
mutans SMW09, which was an exception to the probiotic
eﬀect of E. faecium WB2000. Nevertheless, planktonic num-
bers of mutans streptococcal strains cultured with E. faecium
WB2000 were lower than those in single culture at 16h.
These results indicate that E. faecium WB2000 in dual cul-
tures possessed bacteriostatic or bactericidal activity against
mutans streptococcal strains. The viable cell numbers of E.
faecium WB2000 in dual cultures also varied. In particular,
the number of E. faecium WB2000 cultured with S. mutans
SMW09 decreased markedly by 16h. Overall, single cultures
of the clinical strains produced various amounts of bioﬁlm,
and the increase or decrease in the number of bacteria in a
reaction was strain dependent. These phenomena depended
on diﬀerences in characteristics among the clinical strains
and intercellular reactions. Deng et al. [25] examined the
eﬀects of S. mutans on E. faecalis bioﬁlm formation using
eight clinical E. faecalis strains with the ability to form
bioﬁlms and found diﬀerences among the strains.
A study of lactobacilli suggested that overgrowth and
superinfection by a probiotic bacterium in the oral cavity
are not a concern, although the stability of the exogenous
bacteria in the oral cavity is unclear. In our previous study
[13], the number of L. salivarius WB21 in saliva reached
a peak on day 15 and did not increase further until day
29. Shimauchi et al. [11] reported that the populations of
L. salivarius in saliva specimens from healthy volunteers in
both test and placebo groups tended to decrease during the
intervention period. Lactic acid bacteria commonly found
in the oral cavity are Lactobacillus spp. and Biﬁdobacterium
spp., whereas Enterococcus spp. are primarily in the large
intestine and rarely in the oral cavity. The stability of E.
faeciumWB2000andmaintenanceofitsactivityinacomplex
oral microﬂora should be examined in the future.
Enterococcus spp. are traditionally regarded as low-grade
pathogens, but have been recovered from the oral cavity,
mainlyfromthedentalplaqueofindividualswithunderlying
diseases in whom opportunistic infections have occurred
[26]. We examined the application of E. faecium WB2000
in oral health maintenance because this strain is harmless
and has rarely been recovered from the oral cavity. For
more than 50 years, E. faecium WB2000 has been used in
traditional Japanese medicine (Strong Wakamoto)t ot r e a t
gastrointestinal discomfort, and E. faecium has been used
more often than E. faecalis to treat gastrointestinal trouble
in humans. Compared with E. faecalis, E. faecium appears
to pose a lower risk for use in foods because its strains
generally possess fewer recognized virulence determinants
[27] probably due to the presence of pheromone-responsive
plasmids. A well-documented example of the safety of
exogenous enterococci is E. faecium strain SF68, which has
been used in pharmaceutical preparations to treat diarrhea
[15, 28]. This organism does not have any enterococcal
virulence factors and is not able to adhere to vascular
epithelial cells or endocardial cells [29]. No case of infection
with probiotic E. faecium strains has ever been reported
in humans. Although additional investigations are required
to clarify the mechanism by which E. faecium inhibits
bioﬁlm formation by cariogenic mutans streptococci and
to determine the stability of the E. faecium population
the present study may provide valuable data regarding
the use of an E. faecium strain as local therapy for oral
infections.
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